title: Combination therapy with flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma.
abstract: Sixty-seven previously untreated patients presenting with clinical stage C prostatic carcinoma with no evidence of distant metastases received combination therapy using the antiandrogen Flutamide and the LHRH agonist [D-Trp6]LHRH ethylamide for an average duration of treatment of 23.5 months. Only five patients have so far shown treatment failure with 91.8% of the patients still in remission at 2 years. Three patients have died from prostate cancer while three have died from other causes, 93.5% of the patients being alive at 2 years. Local control was achieved rapidly in all except one patient. Urinary obstruction and hydronephrosis were corrected in all cases. When comparing to recent data obtained after single endocrine therapy (orchiectomy or estrogens), or radiotherapy, the rate of treatment failure at 2 years is 3.5-fold lower after combination therapy (8.2%) than monotherapy (28.4%). The death rate at 2 years following start of the combination therapy is 6.5% while it is on average 22.2% (3.4-fold higher) in the studies using monotherapy (orchiectomy or estrogens) or radiotherapy. The present data suggest that treatment of prostate cancer with combination therapy before clinical evidence of dissemination of the disease permits a better response which is possibly explained, at least in part, by the lower degree of dedifferentiation and heterogeneity of the tumors.
authors.affiliation: Department of Molecular Endocrinology, Laval University Medical Center, Quebec, Canada.
authors.forename: A
authors.initials: A
authors.lastname: Dupont
authors.forename: F
authors.initials: F
authors.lastname: Labrie
authors.forename: M
authors.initials: M
authors.lastname: Giguere
authors.forename: J P
authors.initials: JP
authors.lastname: Borsanyi
authors.forename: Y
authors.initials: Y
authors.lastname: Lacourciere
authors.forename: N
authors.initials: N
authors.lastname: Bergeron
authors.forename: L
authors.initials: L
authors.lastname: Cusan
authors.forename: A
authors.initials: A
authors.lastname: Belanger
authors.forename: J
authors.initials: J
authors.lastname: Emond
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000188:drug therapy; D000305:Adrenal Cortex Hormones / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D005485:Flutamide / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013739:Testosterone / Q000097:blood; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
chemical_list: D000305:Adrenal Cortex Hormones; D003692:Delayed-Action Preparations; D006065:Gonadotropins, Pituitary; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; C019176:Tryptal; D005485:Flutamide; D000135:Acid Phosphatase